Nivolumab-Ipilimumab for Non-Small Cell Lung Cancer - Details


( Last Updated : March 23, 2021)
Generic Name:
Nivolumab in combination with Ipilimumab
Project Status:
Complete
Therapeutic Area:
NSCLC
Manufacturer:
Bristol-Myers Squibb
Brand Name:
Opdivo in combination with Yervoy
Project Line:
Reimbursement Review
Project Number:
PC0218-000
NOC Date:

Details


Strength:
10 mg/mL
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (NSCLC)
Funding Request:
Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations
Review Status:
Notification to Implement Issued
Pre Noc Submission:
Yes
Sponsor:
Bristol-Myers Squibb
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.